UP!
 |
|
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: SPPI S&P 600 Component |
| Industry | Pharmaceuticals |
| Headquarters | Henderson, Nevada |
|
Key people
|
R. Shrotriya, Chief Executive Officer |
| Website | www.spectrumpharm.com |
Spectrum Pharmaceuticals is an American biopharmaceutical company. The company is located in Irvine, California.
Spectrum develops and markets drugs for treatments in oncology.
A number of drugs are currently investigated in clinical trials.
Spectrum terminated the development of Ozarelix, a luteinizing hormone releasing hormone antagonist for the treatment of benign prostatic hypertrophy in 2010. Other previous drug candidates included ortataxel for the treatment of taxane-refractory tumors, and satraplatin for non-small cell lung cancer.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-08 | Future report Set alerts | |
| Q2 2022 | 2022-08-11 | -0.17 | -0.17 |
| Q1 2022 | 2022-05-12 | -0.09 | -0.09 |
| Q4 2021 | 2022-03-17 | -0.26 | -0.26 |
| Q3 2021 | 2021-11-10 | -0.21 | -0.21 |
| Q2 2021 | 2021-08-12 | 0.00 | 0.00 |
| Q1 2021 | 2021-05-13 | -0.25 | -0.25 |
| Q4 2020 | 2021-03-30 | -0.29 | -0.29 |
| Q3 2020 | 2020-11-04 | -0.37 | -0.37 |
| Q2 2020 | 2020-08-10 | -0.28 | -0.29 |
| 2016-05-09 | Reiterated Rating | Jefferies Group | Hold | $5.00 to $6.00 |
| 2016-03-15 | Reiterated Rating | FBR & Co. | Outperform | $10.00 |
| 2016-03-15 | Reiterated Rating | FBR & Co | Outperform | $10.00 |
| 2016-03-14 | Reiterated Rating | HC Wainwright | Buy | |
| 2016-03-09 | Reiterated Rating | FBR & Co. | Outperform | |
| 2016-02-26 | Reiterated Rating | Jefferies Group | Hold | $5.00 |
| 2016-02-17 | Reiterated Rating | Jefferies | Hold | $6.00 to $5.00 |
| 2016-02-17 | Reiterated Rating | Jefferies Group | Hold | $6.00 to $5.00 |
| 2016-02-16 | Lower Price Target | Jefferies Group | Hold | $6.00 to $5.00 |
| 2015-11-05 | Lower Price Target | RBC Capital | Outperform | $13.00 to $12.00 |
| 2015-11-05 | Lower Price Target | Royal Bank Of Canada | Outperform | $13.00 to $12.00 |
| 2015-10-27 | Reiterated Rating | HC Wainwright | Buy | |
| 2015-10-23 | Reiterated Rating | RBC Capital | Buy | $13.00 |
| 2015-08-18 | Reiterated Rating | Roth Capital | Neutral | $6.00 |
| 2015-08-07 | Boost Price Target | RBC Capital | Outperform | $12.00 to $13.00 |
| 2015-06-29 | Initiated Coverage | HC Wainwright | Buy | $10.00 |
| 2015-06-05 | Reiterated Rating | HC Wainwright | Buy | |
| 2015-05-16 | Reiterated Rating | HC Wainwright | Buy | $13.00 to $10.00 |
| 2015-04-01 | Initiated Coverage | FBR & Co. | Outperform | $9.00 |
| 2015-03-16 | Lower Price Target | Jefferies Group | Hold | $8.00 to $6.00 |
| 2015-02-26 | Set Price Target | Roth Capital | Hold | $7.00 |
| 2015-02-23 | Set Price Target | HC Wainwright | Buy | $15.00 |
| 2015-02-23 | Downgrade | Roth Capital | Buy to Neutral | $15.00 to $7.00 |
| 2014-11-19 | Initiated Coverage | Jefferies Group | Hold | $8.00 |
| 2014-07-15 | Boost Price Target | R. F. Lafferty | Sell to Neutral | $7.50 |
| 2014-07-07 | Reiterated Rating | Roth Capital | Positive | |
| 2014-02-06 | Reiterated Rating | Roth Capital | Buy | |
| 2013-10-07 | Initiated Coverage | HC Wainwright | Buy | $15.00 |
| 2013-05-29 | Initiated | Burrill Institutional Research | Mkt Outperform | $12 |
| 2013-03-13 | Downgrade | WallachBeth | Buy to Sell | $20 to $5.50 |
| 2011-05-02 | Reiterated | MLV Capital | Buy | $12.50 to $20.50 |
| 2011-03-25 | Initiated | RBC Capital Mkts | Outperform | $12 |
| 2010-12-07 | Reiterated | Morgan Joseph | Buy | $8 to $10 |
| 2010-01-12 | Upgrade | Morgan Joseph | Hold to Buy | $8 |
| 2009-10-14 | Reiterated | Rodman & Renshaw | Mkt Outperform | $10 to $8 |
| 2009-09-08 | Downgrade | Morgan Joseph | Buy to Hold | |
| 2008-09-09 | Initiated | Morgan Joseph | Buy | $5 |
| 2008-04-23 | Downgrade | Oppenheimer | Outperform to Perform | |
| 2008-03-18 | Downgrade | Brean Murray | Buy to Hold | |
| 2007-10-31 | Reiterated | Rodman & Renshaw | Mkt Outperform | $8 to $6 |
| 2007-07-25 | Upgrade | Brean Murray | Sell to Hold | |
| 2007-07-25 | Reiterated | Lazard Capital | Buy | $11 to $6 |
| 2007-07-25 | Downgrade | Friedman Billings | Outperform to Mkt Perform | $12.25 to $5.50 |
| 2007-07-23 | Downgrade | Brean Murray | Buy to Sell | $11 to $4 |
| 2016-05-09 | Reiterated Rating | Jefferies Group | Hold | $5.00 to $6.00 |
| 2016-03-15 | Reiterated Rating | FBR & Co. | Outperform | $10.00 |
| 2016-03-15 | Reiterated Rating | FBR & Co | Outperform | $10.00 |
| 2016-03-14 | Reiterated Rating | HC Wainwright | Buy | |
| 2016-03-09 | Reiterated Rating | FBR & Co. | Outperform |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In SPPI 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| SHROTRIYA RAJESH C MD Chairman, CEO & President | 1.20% (789977) | ENMD / SPPI / |
| Turgeon Joseph W. Chief Commercial Officer | 0.48% (316509) | SPPI / |
| Riga Thomas J Chief Operating Officer | 0.37% (243854) | SPPI / |
| KUMARIA SHYAM K Sr. Vice President Finance | 0.33% (218471) | SPPI / |
| GUSTAFSON KURT A EVP & Chief Financial Officer | 0.28% (187193) | HALO / SPPI / XNCR / |
| Keller Joseph Kenneth EVP & Chief Operating Officer | 0.26% (168000) | SPPI / |
| Shields James Chief Commercial Officer | 0.13% (87806) | SPPI / |
| Gagnon Gilles | 0.13% (82500) | SPPI / |
| ALLEN LEE F MD PhD Chief Medical Officer | 0.12% (80381) | AMAG / ARGS / SPPI / |
| Krassner Stuart Mitchell | 0.12% (79057) | SPPI / |
| LENAZ LUIGI MD | 0.11% (69077) | SPPI / |
| Scott Brett L Acting Chief Financial Officer | 0.07% (45661) | BIOL / SPPI / |
| COHEN RAYMOND W | 0.07% (43125) | BLFS / SPPI / |
| TIDMARSH GEORGE F CSO AND HEAD OF R&D OPERATIONS | 0.06% (40000) | LJPC / SPPI / |
| Vyas Dolatrai | 0.06% (37079) | SPPI / |
| MEHTA DILIP J MD PHD | 0.05% (32000) | SPPI / |
| MAIDA ANTHONY E III | 0.03% (22988) | ONCS / SPPI / |
| Arora Krishan K | 0.02% (15000) | SPPI / |
| GUETH ANTON | 0.02% (11000) | ATRS / NAVB / SPPI / |
UM